12:00 AM
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Makena hydroxyprogesterone caproate injection regulatory update

FDA said in a statement that it found no major safety problems in an analysis of compounded hydroxyprogesterone caproate products, which have been used as a cheaper alternative to KV's preterm birth drug Makena hydroxyprogesterone caproate. However, FDA said approved drug products such as Makena "provide a greater assurance of safety and effectiveness than do compounded products." The agency...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >